Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.10
Bid: 7.10
Ask: 7.48
Change: 0.29 (4.14%)
Spread: 0.38 (5.352%)
Open: 7.02
High: 7.10
Low: 7.00
Prev. Close: 7.00
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

20 Mar 2007 16:12

Synairgen plc20 March 2007 TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Identity of the issuer or the underlying issuer of existing Synairgen plcshares to which voting rights are attached: 2. Reason for the notification (please tick the appropriate box or boxes) An acquisition or disposal of voting rights An acquisition or disposal of financial instruments which may result in the acquisition ofshares already issued to which voting rights are attached An event changing the breakdown of voting rights Other (please specify): DTR transitional notification of holdings X 3. Full name of person(s) subject to the notification Lansdowne Partners Limited being theobligation: General Partner of Lansdowne Partners Limited Partnership Lansdowne UK Equity Fund Limited Lansdowne Partners International Limited 4. Full name of shareholder(s) (if different from 3.): Morstan Nominees Ltd (Registered Shareholder) 5. Date of the transaction (and date on which the threshold is N/Acrossed or reached if different): 6. Date on which issuer notified: N/A 7. Threshold(s) that is/are crossed or reached: 8% 8. Notified details: A: Voting rights attached to shares Class/type of Situation previous to Resulting situation after the triggering transactionshares the Triggering transaction if possible Number of Number of Number of Number of voting rights % of voting rightsusing the ISIN Shares Voting sharesCODE Rights Direct Direct Indirect Direct Indirect Ordinary Shares 1,950,000 1,950,000 0 0 1,950,000 0.00% 8.99% B: Financial Instruments Resulting situation after the triggering transaction Type of financial Expiration date Exercise/ Conversion Number of voting rights % of votinginstrument Period/ Date that may be acquired if rights the instrument is exercised/ converted N/A N/A N/A N/A N/A Total (A+B) Number of voting rights % of voting rights 1,950,000 8.99% 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectivelyheld, if applicable: Lansdowne Partners International Limited is the parent undertaking of Lansdowne Partners Limited. Proxy Voting: 10. Name of the proxy holder: Lansdowne Partners Limited 11. Number of voting rights proxy holder will cease to hold: 12. Date on which proxy holder will cease to hold votingrights: 13. Additional information: Lansdowne Partners Limited being the General Partner of Lansdowne Partners Limited Partnership ("LPLP") controls 1,950,000 voting rights representing 8.99% of the total voting rights. Lansdowne UK Equity Fund Limited owns 1,854,751 voting rights representing 8.55% of the total voting rights. The balancing 0.44% of voting rights is held on behalf of other client funds managed by LPLP. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Jun 20187:00 amRNSPositive SNG001 Biomarker Data in COPD Patients
26th Jun 20181:05 pmRNSHolding(s) in Company
22nd Jun 201811:42 amRNSResult of AGM
22nd Jun 20187:00 amRNSSynairgen Safety Data with SNG001 in COPD Patients
17th May 20187:00 amRNSPosting of Annual Report and Notice of AGM
16th Apr 20184:29 pmRNSHolding(s) in Company
6th Apr 201812:14 pmRNSGrant of Options
3rd Apr 20185:21 pmRNSHolding(s) in Company
15th Mar 20183:13 pmRNSIssue of Equity
15th Mar 20183:11 pmRNSHolding(s) in Company
15th Mar 20187:00 amRNSPreliminary results for year ended 31 Dec 2017
7th Feb 20187:00 amRNSSynairgen starts dosing in Phase II COPD study
14th Dec 20177:00 amRNSUpdate on LOXL2 Programme&Pharmaxis Collaboration
8th Nov 20174:31 pmRNSHolding(s) in Company
27th Sep 20177:00 amRNSInterim results for six months ended 30 June 2017
27th Sep 20177:00 amRNSData update and clinical plan for COPD
13th Sep 201712:44 pmRNSHolding(s) in Company
6th Sep 20177:00 amRNSLOXL2 Inhibitor Update.
28th Jun 201712:41 pmRNSResult of AGM
5th Jun 20177:00 amRNSPosting of Annual Report and Notice of AGM
17th May 20177:00 amRNSPreliminary Results
27th Apr 20177:00 amRNSAZD9412 Update
27th Mar 20177:00 amRNSHolding(s) in Company
13th Mar 20173:10 pmRNSHolding(s) in Company
10th Mar 20178:34 amRNSAdditional Positive Data in Lung Fibrosis
17th Jan 20172:46 pmRNSHolding(s) in Company
13th Oct 201610:44 amRNSHolding(s) in Company
12th Oct 20167:00 amRNSAZD9412 Clinical Trial Update
22nd Sep 20167:00 amRNSInterim results for six months ended 30 June 2016
8th Sep 20167:00 amRNSNotice of Interim Results
14th Jun 201612:00 pmRNSResult of AGM
17th May 20167:00 amRNSPosting of Annual Report and Notice of AGM
21st Apr 20162:14 pmRNSHolding(s) in Company
23rd Mar 20167:00 amRNSExercise of Options
22nd Mar 20167:00 amRNSPreliminary results for the year ended 31 Dec 2015
22nd Mar 20167:00 amRNSPositive LOXL2 results
3rd Mar 20167:00 amRNSNotice of Preliminary Results
16th Nov 20154:11 pmRNSAdoption of FRS 101 - Reduced Disclosure Framework
13th Nov 20153:08 pmRNSHolding(s) in Company
13th Nov 201511:41 amRNSHolding(s) in Company
13th Nov 20157:00 amRNSHolding(s) in Company
12th Nov 20157:00 amRNSDirectors' Share Purchase
28th Oct 20157:00 amRNSGrant of options
16th Sep 20157:00 amRNSInterim Results
21st Aug 20157:00 amRNSNotice of Interim Results
5th Aug 20157:00 amRNSSynairgen announces research collaboration
22nd Jul 20157:00 amRNSAstraZeneca commences Phase II Trial
22nd Jun 20151:41 pmRNSResult of AGM
2nd Jun 20159:37 amRNSHolding(s) in Company
15th May 201511:04 amRNSNotice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.